Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced that it has received market approval from China’s National Medical Products Administration (NMPA) for its generic version of Allergan’s (NYSE: AGN) Lumigan (bimatoprost), a treatment for glaucoma.
The product, marketed under the Chinese trade name JingBeiQing, is the first preservative-free single-dose bimatoprost eye drop designed to reduce intraocular pressure in patients with open-angle glaucoma and high intraocular pressure. The preservative-free formulation is significant as it helps prevent damage to the ocular surface in glaucoma patients who require long-term medication use, thus avoiding issues associated with preservatives. Additionally, this medication is expected to enhance patient comfort and reduce the risk of preservative sensitivity. The daily dosing frequency is also aimed at improving patient compliance with treatment.- Flcube.com
